Literature DB >> 26320088

Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents.

Andrea Spallarossa1, Chiara Caneva2, Matteo Caviglia2, Silvana Alfei2, Stefania Butini3, Giuseppe Campiani3, Sandra Gemma3, Margherita Brindisi3, Daniela M Zisterer4, Sandra A Bright4, Clive D Williams4, Emmanuele Crespan5, Giovanni Maga5, Giuseppina Sanna6, Ilenia Delogu6, Gabriella Collu6, Roberta Loddo6.   

Abstract

A new series of indole-based analogues were recently identified as potential anticancer agents. The Knoevenagel-type indoles herein presented were prepared via a one-pot condensation of iminium salts with active methylene reagents and were isolated as single geometric isomers. Biological evaluation in different cell-based assays revealed an antiproliferative activity for some analogues already in the nanomolar range against leukaemia, breast and renal cancer cell lines. To explain these effects, the most promising analogues of the series were engaged in further cell-based studies. Compounds 5e, l, p and 6a, b highlighted a pro-apoptotic potential being able to induce apoptosis in HL60, K562 and MCF-7 cell lines in a dose and time-dependent manner. The ability of these compounds to arrest cell cycle at the G2/M phase inspired the immunofluorescence studies which allowed us to identify tubulin as a potential target for compounds 5l and 6b.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antiproliferative agents; Indoles; Pro-apoptotic agents; Tubulin immunostaining

Mesh:

Substances:

Year:  2015        PMID: 26320088     DOI: 10.1016/j.ejmech.2015.08.009

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Tris(2-Aminoethyl)Amine/Metal Oxides Hybrid Materials-Preparation, Characterization and Catalytic Application.

Authors:  Katarzyna Stawicka; Maria Ziolek
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.